A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of monotherapy ontuxizumab (MORAb-004) plus best supportive care in patients with chemorefractory metastatic colorectal cancer

Axel F Grothey, Jonathan R. Strosberg, Lindsay A. Renfro, Herbert I. Hurwitz, John L. Marshall, Howard Safran, Michael J. Guarino, George P. Kim, J. R. Hecht, Susan C. Weil, John Heyburn, Wenquan Wang, Charles Schweizer, Daniel J. O'Shannessy, Luis Alberto Diaz

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Purpose: The purpose of this study was to evaluate the safety and efficacy of ontuxizumab (MORAb-004), a monoclonal antibody that interferes with endosialin (tumor endothelial marker-1) function, in patients with chemorefractory metastatic colorectal cancer and to identify a responsive patient population based on biomarkers. Experimental Design: This was a randomized, double-blind, placebo-controlled, phase II study. Patients were randomly assigned in a 2:1 ratio to receive weekly intravenous ontuxizumab (8 mg/kg) or placebo plus best supportive care until progression or unacceptable toxicity. Tissue and blood biomarkers were evaluated for their ability to identify a patient population that was responsive to ontuxizumab. Results: A total of 126 patients were enrolled. No significant difference between the ontuxizumab and placebo groups was evident for the primary endpoint of progression-free survival (PFS), with a median PFS of 8.1 weeks in each group (HR, 1.13; 95% confidence interval, 0.76-1.67; P = 0.53). There were no significant differences between groups for overall survival (OS) or overall response rate (ORR). The most common treatment-emergent adverse events (TEAEs) in the ontuxizumab group (vs. the placebo group, respectively) were fatigue (53.7% vs. 47.5%), nausea (39.0% vs. 35.0%), decreased appetite (34.1% vs. 27.5%), and constipation (28.0% vs. 32.5%). The most common grade 3/4 TEAE in the ontuxizumab group versus placebo was back pain (11.0% vs. 0%). No single biomarker clearly identified patients responsive to ontuxizumab. Conclusions: No benefit with ontuxizumab monotherapy compared with placebo for clinical response parameters of PFS, OS, or ORR was demonstrated. Ontuxizumab was well tolerated.

Original languageEnglish (US)
Pages (from-to)316-325
Number of pages10
JournalClinical Cancer Research
Volume24
Issue number2
DOIs
StatePublished - Jan 15 2018

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of monotherapy ontuxizumab (MORAb-004) plus best supportive care in patients with chemorefractory metastatic colorectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Grothey, A. F., Strosberg, J. R., Renfro, L. A., Hurwitz, H. I., Marshall, J. L., Safran, H., Guarino, M. J., Kim, G. P., Hecht, J. R., Weil, S. C., Heyburn, J., Wang, W., Schweizer, C., O'Shannessy, D. J., & Diaz, L. A. (2018). A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of monotherapy ontuxizumab (MORAb-004) plus best supportive care in patients with chemorefractory metastatic colorectal cancer. Clinical Cancer Research, 24(2), 316-325. https://doi.org/10.1158/1078-0432.CCR-17-1558